CRWM
IBB icon

Castle Rock Wealth Management’s iShares Biotechnology ETF IBB Stock Holding History

Castle Rock Wealth Management’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$388K Buy
1,910
+480
+34% +$96.3K 0.07% 189
2026
Q2 		$272K Sell
1,430
-26
-2% -$4.47K 0.05% 239
2026
Q1 		$247K Buy
1,456
+4
+0.3% +$684 0.05% 240
2025
Q4 		$251K Buy
1,452
+45
+3% +$7.31K 0.05% 235
2025
Q3 		$209K Buy
+1,407
New +$192K 0.05% 249
2025
Q2 		– Sell
-2,185
Closed -$275K – 250
2025
Q1 		$275K Buy
2,185
+22
+1% +$2.98K 0.07% 196
2024
Q4 		$295K Sell
2,163
-426
-16% -$59.9K 0.07% 194
2024
Q3 		$369K Buy
2,589
+62
+2% +$8.97K 0.09% 178
2024
Q2 		$346K Buy
2,527
+238
+10% +$31.8K 0.09% 183
2024
Q1 		$296K Buy
2,289
+87
+4% +$11.9K 0.08% 192
2023
Q4 		$299K Buy
+2,202
New +$269K 0.09% 182
2023
Q2 		– Sell
-1,566
Closed -$205K – 218
2023
Q1 		$205K Sell
1,566
-329
-17% -$43.1K 0.07% 206
2022
Q4 		$260K Buy
+1,895
New +$245K 0.12% 184
2022
Q2 		– Sell
-1,898
Closed -$243K – 227
2022
Q1 		$243K Sell
1,898
-444
-19% -$57.8K 0.11% 201
2021
Q4 		$301K Sell
2,342
-241
-9% -$37.3K 0.12% 187
2021
Q3 		$407K Buy
2,583
+9
+0.3% +$1.51K 0.14% 170
2021
Q2 		$445K Sell
2,574
-54
-2% -$8.32K 0.16% 157
2021
Q1 		$406K Buy
2,628
+125
+5% +$19.9K 0.16% 175
2020
Q4 		$412K Buy
2,503
+501
+25% +$71.6K 0.17% 169
2020
Q3 		$269K Buy
2,002
+493
+33% +$66.9K 0.18% 137
2020
Q2 		$208K Buy
+1,509
New +$192K 0.12% 181
2020
Q1 		– Sell
-2,117
Closed -$260K – 149
2019
Q4 		$260K Sell
2,117
-13
-0.6% -$1.45K 0.23% 135
2019
Q3 		$234K Sell
2,130
-677
-24% -$70.9K 0.24% 128
2019
Q2 		$311K Buy
+2,807
New +$299K 0.35% 98
2018
Q4 		– Sell
-2,169
Closed -$235K – 49
2018
Q3 		$235K Buy
2,169
+286
+15% +$33.7K 0.37% 97
2018
Q2 		$207K Buy
+1,883
New +$201K 0.28% 112

Other funds holding IBB

AC
Apella Capital West Hartford, Connecticut $7.88B AUM 10.78% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return
NRS
Neville Rodie & Shaw New York $1.48B AUM 34.49% 1-Year Est. Return
MCM
Monument Capital Management Alexandria, Virginia $480M AUM 43.68% 1-Year Est. Return
CCA
Cadent Capital Advisors Tulsa, Oklahoma $466M AUM 30.56% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
AIM
Acropolis Investment Management St. Louis, Missouri $2.49B AUM 10.8% 1-Year Est. Return
SDAM
Shulman DeMeo Asset Management Lake Success, New York $505M AUM 16.86% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
FWCM
Ferguson Wellman Capital Management Portland, Oregon $8.38B AUM 25.07% 1-Year Est. Return

Castle Rock Wealth Management's IBB Position: Q3 2026 in Review

Castle Rock Wealth Management increased its iShares Biotechnology ETF (IBB) stake by 34% in Q3 2026, buying an estimated $96.3K and bringing the position to 1,910 shares worth $388K. The position accounts for 0.07% of the portfolio, ranked #189.

Castle Rock Wealth Management first reported a position in IBB in Q2 2018 and has held it in 26 quarters since. The position peaked at $445K in Q2 2021. 45 funds tracked by Wall St. Rank hold IBB as of Q3 2026.

  • Castle Rock Wealth Management held 1,910 shares of iShares Biotechnology ETF worth $388K as of Q3 2026.
  • Castle Rock Wealth Management bought 480 iShares Biotechnology ETF shares in Q3 2026, an estimated $96.3K.
  • iShares Biotechnology ETF made up 0.07% of Castle Rock Wealth Management's portfolio in Q3 2026, its #189 holding.
  • Castle Rock Wealth Management first reported a position in iShares Biotechnology ETF in Q2 2018 and has held it in 26 quarters since.
  • Castle Rock Wealth Management's iShares Biotechnology ETF position peaked at $445K in Q2 2021.
  • 45 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2026.

Based on Castle Rock Wealth Management's 13F filing for Q3 2026, filed 9 Oct 2026.